Post-earnings recap
Reported
Tue, Oct 29, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
PTC Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may leave investors uncertain about the company's future performance. Overall, the market reacted negatively, reflecting concerns about the company's current trajectory and profitability challenges.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.06 | N/A | -18.65% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current market conditions impacting growth. They did not provide any forward-looking guidance.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability.